the authors thank dr . pete mullen and rosemary yu of the penn laboratory for review of the manuscript . this work was undertaken in part thanks to funding from the crc program ( lzp ) , the oicr through funding provided by the province of ontario ( lzp ) , the cbcf ( ap ) and the ontario ministry of health and long term care . the views expressed do not necessarily reflect those of the ontario ministry of health and long term care .
statins are promising anticancer agents that target the mevalonate pathway . 
 tumor cells are sensitive to depletion of mevalonate - derived products but this activity triggers a homeostatic feedback loop that blunts statin efficacy . 
 we showed that dipyridamole inhibits this feedback response and potentiates statin antitumor activity . 
 this study identifies statins plus dypridamole as a preclinically effective combination of approved agents .